

Altered signalling in CB₁-5HT_{2A} receptor heteromers in olfactory neuroepithelium cells of schizophrenia patients is modulated by cannabis use

Estefanía Moreno¹, Daniel Guinart², Marta Barrera-Conde³, Liliana Galindo², Aida Cuenca-Royo³, Cristina Fernandez³, Arnau Cordomi⁴, Leonardo Pardo⁴, Victor Perez², Enric I. Canela¹, Vicent Casadó¹, Rafael De la Torre³, Patricia Robledo³

¹Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, UB, Barcelona, Spain and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.

estefaniamoreno@ub.edu

²Neuropsychiatry and Addictions Institute (INAD) of Parc de Salut Mar, Barcelona, Spain and Centro de Investigación Biomédica En Red de Salud Mental, Madrid, Spain.

³Integrative Pharmacology and Systems Neuroscience, Neuroscience Research Programme, IMIM-Hospital del Mar Research Institute, Barcelona, Spain.

probledo@imim.es

⁴Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain,

Schizophrenia (SCZ) is a complex, severe and debilitating mental disorder that causes a substantial clinical, familiar and economic burden, but its aetiology and underlying pathophysiology remain unknown. Dysregulations in the serotonergic and the endocannabinoid systems have been discussed as potential causes of schizophrenia, but the difficulty in obtaining central nervous system tissue samples and cells in living subjects has limited its exploration. Due to its low-invasiveness and high scalability, olfactory neuroepithelium (ON) cell models are becoming a promising surrogate system to explore neuronal biomarkers in schizophrenia, providing a unique opportunity to unveil novel potential molecular targets for psychopharmacology research. Chronic cannabis use induces several deleterious effects including cognitive and mood alterations by acting on the endocannabinoid system, and by modulating the activity of other neurotransmitters in the brain. Recently, we have demonstrated that CB₁ cannabinoid receptor (CB₁R) and serotonergic 2A receptor (5HT_{2A}R) heteromers are expressed and functionally active in the brain of mice, where they specifically mediate the memory impairment induced by cannabis (Viñals et al. 2015). Moreover, we revealed the presence of functional CB₁R-5HT_{2A}R heteromers in ON cells of healthy cannabis users (HC/c) and control subjects non-cannabis users (HC/nc), showing a significant negative correlation between the expression levels of this heterodimer and attention and working memory performance (Galindo et al. 2018). In this study, we focused on the ON to investigate CB₁R-5HT_{2A}R heteromer expression and functionality in SCZ patients, and evaluated whether cannabis use in a sub-population of SCZ patients (SCZ/c) modulated these parameters. In addition, we examined possible associations between heteromer expression/functionality and cognitive processes, psychopathological and functional variables in SCZ patients. Finally, we assessed the effects of antipsychotic treatment and its interaction with cannabis use on CB₁R-5HT_{2A}R heteromer functionality. The major finding in this study was that the signalling of CB₁R-5HT_{2A}R heteromers via cAMP and pERK in ON cells is not observed in SCZ/nc, while in SCZ/c the fingerprint of the heteromer is maintained. In addition, we report that clozapine treatment in ON cells of HC/nc also modified the functionality of the heteromer, but not in ON cells of HC/c. These findings point to changes in the molecular conformation of CB₁R-5HT_{2A}R heteromers in treated SCZ patients, which are prevented by cannabis use. Finally, cognitive deficits were present in both SCZ/nc and SCZ/c, suggesting that changes in the functionality of the heteromer may not influence cognitive impairment in SCZ. More studies are needed to further explore the role of CB₁R-5HT_{2A}R heteromer and its clinical significance in the development of SCZ, and in the effects of different antipsychotic medications.

References:

1. Viñals X et al., 2015. Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB₁ and Serotonin 5-HT_{2A} Receptors. PLoS Biol. 2015 Jul 9;13(7):e1002194. doi: 10.1371/journal.pbio.1002194.
2. Galindo L et al., 2018 Cannabis Users Show Enhanced Expression of CB₁-5HT_{2A} Receptor Heteromers in Olfactory Neuroepithelium Cells. Mol Neurobiol. 2018 Jan 2. doi: 10.1007/s12035-017-0833-7.

Key words: schizophrenia, CB₁-5HT_{2A} heteromers, cannabis, pro-neurons, human, olfactory neuroepithelium.

Type of presentation: Poster.